search button
Open Access

Synergistic anti‑proliferative and pro‑apoptotic activities of 5F and cisplatin in human non‑small cell lung cancer NCI‑H23 cells

  • Authors:
    • Yuchan Li
    • Wende Li
    • Wusheng Deng
    • Yuhong Gan
    • Kefeng Wu
    • Jie Sun

  • View Affiliations

  • Published online on: August 28, 2017     https://doi.org/10.3892/ol.2017.6848
  • Pages: 5347-5353

  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Two‑drug combination chemotherapy, often inclu­ding cisplatin and one other drug, remains the standard of care for patients with advanced non‑small cell lung cancer (NSCLC). To improve the treatment of late‑stage NSCLC and decrease the toxicity of combination chemotherapy, the search for novel drugs remains vigorous. Ent‑11α‑hydroxy‑15‑oxo‑kaur‑16‑en‑19‑oic acid (5F), a bioactive compound isolated from the herb Pteris semipinnata L., has previously been shown to induce apoptosis and inhibit proliferation in various cancer cells. One outstanding property of 5F is its minimal side effects. In the present study, 5F was combined with cisplatin to treat NCI‑H23 cells; proliferation, apoptosis and cell cycle arrest were measured by an MTT assay, Annexin V staining/flow cytometry and propidium iodide staining/flow cytometry, respectively. The messenger RNA levels of β‑catenin, glycogen synthase kinase (GSK)‑3β, c‑Myc and cyclin D1 were determined by reverse transcription‑quantitative polymerase chain reaction, and the protein levels of β‑catenin and GSK‑3β were measured by western blot analysis. The results revealed that 5F and cisplatin synergistically induced apoptosis and inhibited cell growth, arrested cell cycles in the G0/G1 phase, downregulated β‑catenin, c‑Myc and cyclin D1, and upregulated GSK‑3β. These findings merit in vivo studies using animal models of NSCLC to confirm the addition of 5F as a third drug to cisplatin‑based combination therapy for late‑stage NSCLC.
View Figures
View References

Related Articles

Journal Cover

November-2017
Volume 14 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Li Y, Li W, Deng W, Gan Y, Wu K and Sun J: Synergistic anti‑proliferative and pro‑apoptotic activities of 5F and cisplatin in human non‑small cell lung cancer NCI‑H23 cells. Oncol Lett 14: 5347-5353, 2017
APA
Li, Y., Li, W., Deng, W., Gan, Y., Wu, K., & Sun, J. (2017). Synergistic anti‑proliferative and pro‑apoptotic activities of 5F and cisplatin in human non‑small cell lung cancer NCI‑H23 cells. Oncology Letters, 14, 5347-5353. https://doi.org/10.3892/ol.2017.6848
MLA
Li, Y., Li, W., Deng, W., Gan, Y., Wu, K., Sun, J."Synergistic anti‑proliferative and pro‑apoptotic activities of 5F and cisplatin in human non‑small cell lung cancer NCI‑H23 cells". Oncology Letters 14.5 (2017): 5347-5353.
Chicago
Li, Y., Li, W., Deng, W., Gan, Y., Wu, K., Sun, J."Synergistic anti‑proliferative and pro‑apoptotic activities of 5F and cisplatin in human non‑small cell lung cancer NCI‑H23 cells". Oncology Letters 14, no. 5 (2017): 5347-5353. https://doi.org/10.3892/ol.2017.6848